Navigation Links
Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
Date:4/27/2009

ies. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions regarding future expectations. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Risks and uncertainties that could affect the Company's future operating results and financial condition generally include, without limitation: (i) the risk that we may not have sufficient funds to operate our business; (ii)our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
8. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
9. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
10. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
11. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Matrix Marketing Group, LLC , ... hired Gem Swartz to head up its account management department as vice president of ... and Amanda bring senior account management and delivery expertise to the growing Matrix Marketing ...
(Date:6/30/2015)...  The Dr. Samadi Prostate Cancer Center in ... suite of new genetic testing methods for men with an ... cancer. Dr. Samadi,s Prostate Cancer Center ... the risk and optimizing the diagnosis of prostate cancer, both ... now offer these revolutionary genetic tests to men with an ...
(Date:6/29/2015)... ... , ... This cutting edge standard making is a madatory tool for use ... WAV-8 is the world’s first cuvette-shaped, solid-state filter that lets metrologists and quality control ... spectrophotometer calibration standards, such as those made from didymium glass were only able to ...
(Date:6/29/2015)... June 29, 2015 BioNano Genomics, Inc., the ... research institutes, announced today that a collaboration led by ... in the creation of the first comprehensive analysis of ... molecule methods for sequencing and genome mapping. This study, ... comprehensive analysis of the contiguous diploid human genome assembly ...
Breaking Biology Technology:Matrix Marketing Group Expands Client Services Team 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3
... 22, 2011 NeurogesX, Inc. (Nasdaq: NGSX ... management therapies, today announced that on July 21, 2011 ... with a private placement to a group of institutional ... expected to receive approximately $20 million in gross proceeds ...
... a significant threat to humans, as emphasized by the recent ... published on July 21st by the Cell Press journal ... of similar and divergent strategies that different toxins use to ... toxic protein derived from the castor bean plant that has ...
... ViroPharma Incorporated,s (Nasdaq: VPHM ) second quarter ... Thursday, July 28, 2011 before the open of the U.S. ... call and live audio webcast at 9:00 a.m. Eastern Time ... will discuss the 2011 second quarter financial results and other ...
Cached Biology Technology:NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4Targeting toxin trafficking 2ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011 2
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... factor for stroke, and its occurrence is closely related ... animals have shown that scavenger receptor class B type ... of scavenger receptor class B type I gene polymorphisms ... the exon 8 C1050T polymorphism, and these polymorphic loci ...
... During the last decade, our understanding of ... novel hypothalamic Arg-Phe-amide- related peptides, kisspeptin and ... the reproductive axis. Kisspeptins are currently recognized ... hypothalamus-pituitary-gonadal axis. Kisspeptin and its receptor, G ...
... The Bert L. and N. Kuggie Vallee Foundation announces, ... The 2013 winners are: Dr. Kirsty L. ... Molecular Biology at the Karolinska Institutet (Stockholm, Sweden) who ... fat cells. Dr. David Tobin, Assistant Professor of ...
Cached Biology News:
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
... Purpose -- The Varian 1200 ... highest level of flexibility and ... affordable, easy-to-use system. The complete ... guarantees success with today's applications ...
Biology Products: